Collegium Pharmaceutical Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Collegium Pharmaceutical - Business Model Canvas & Investor Guide
A concise Business Model Canvas that outlines Collegium Pharmaceutical's strategy for developing and commercializing pain and CNS therapies-highlighting core value propositions, customer segments, key partnerships, and revenue streams, and showing how the company differentiates and scales with a focus on abuse – deterrent formulations and improved patient care. Download the full Word/Excel canvas for a section-by-section breakdown tailored to investors, consultants, and founders seeking actionable insights.
Partnerships
Strategic Contract Manufacturing Organizations
Collegium Pharmaceutical outsources production of its complex DETERx (extended – release abuse – deterrent) formulations to strategic contract manufacturing organizations (CMOs), enabling scalable output-Collegium reported COGS of $85.4M in 2024 while maintaining FDA compliance across all sites.
Major Pharmaceutical Wholesalers
Collegium relies on major wholesalers-AmerisourceBergen, Cardinal Health, McKesson-to handle nationwide logistics and delivery, enabling reach to ~60,000 US pharmacies and facilities; these partners processed a large share of opioid and non-opioid Rx distribution volumes in 2024.
Keeping strong credit lines and service SLAs with these distributors is vital: a one-week supply disruption could cut quarterly revenues by double digits given Collegium's concentrated channel footprint and inventory turns.
Payers and Pharmacy Benefit Managers
Collaborations with payers and PBMs secure formulary placement for Xtampza ER and Belbuca through rebate deals and value-based contracts; in 2024 Collegium reported payer discounts cutting list-price realization by ~30%, with PBM-preferred status correlating to a ~40% higher script share. Effective negotiation and contract management therefore drive net realized price and market share.
Academic and Clinical Research Organizations
Collegium partners with top academic and clinical research centers to run clinical trials and post-marketing studies that produced key data for approvals and label extensions; in 2024 these collaborations supported >15 studies and helped sustain combined R&D spend of $67.4M.
These partnerships validate safety and efficacy for its abuse-deterrent opioid portfolio, strengthening market differentiation and payer coverage through peer-reviewed evidence and real-world outcomes.
- Supported >15 studies in 2024
- R&D spend $67.4M (2024)
- Evidence drove label updates and payer discussions
Strategic Acquisition and Licensing Partners
Collegium fuels inorganic growth by acquiring or licensing products to broaden its CNS and pain portfolio; the 2021 acquisition of Ironshore Pharmaceuticals added ADHD assets and contributed to a revenue base that reached $141.6M in FY2023, supporting pipeline expansion.
- Acquisitions/licensing drive diversification
- Ironshore deal added ADHD assets (2021)
- FY2023 revenue $141.6M supports R&D
- Partners supply complementary assets for pipeline growth
Collegium scales DETERx via CMOs, top wholesalers, payers & research - $141.6M FY23
Collegium partners with CMOs, top US wholesalers (AmerisourceBergen, Cardinal, McKesson), payers/PBMs, academic research centers, and M&A/licensing partners to scale DETERx production, secure formulary access, generate clinical evidence, and diversify the portfolio-2024 metrics: COGS $85.4M, R&D $67.4M, FY2023 revenue $141.6M; payer discounts ~30%, PBM-preferred scripts +40%.
| Partner | Role | Key 2024 metric |
|---|---|---|
| CMOs | Manufacturing | COGS $85.4M |
| Wholesalers | Distribution | Reach ~60,000 pharmacies |
| Payers/PBMs | Formulary access | List realization -30% |
| Research centers | Clinical evidence | >15 studies |
| M&A/licensing | Portfolio growth | FY2023 revenue $141.6M |
What is included in the product
Detailed Word Document
A concise Business Model Canvas for Collegium Pharmaceutical detailing customer segments, channels, value propositions, revenue streams, key activities, resources, partnerships, cost structure, and competitive advantages tied to strengths, weaknesses, opportunities, and threats.
Customizable Excel Spreadsheet
High-level view of Collegium Pharmaceutical's business model with editable cells, quickly highlighting how its specialty pain-management portfolio, partnerships, and reimbursement strategies relieve stakeholder pain points.
Activities
Commercial Execution and Sales Force Management
Collegium deploys a specialized sales force to educate prescribers on Xtampza ER and other differentiated pain therapies, combining targeted marketing and ~20-30 monthly field calls per rep to drive prescriptions; in 2024 Collegium reported net product revenue of $44.6M, so success is measured by share captured from non-abuse-deterrent opioids and prescription growth versus legacy alternatives.
Regulatory Compliance and Quality Assurance
Navigating FDA and DEA rules is continuous: Collegium Pharmaceutical (NASD: COLL) spends an estimated $18-22M annually on compliance controls and reported 42 adverse-event reviews in 2024; manufacturing and marketing must meet cGMP and REMS label requirements, or risk FDA warning letters and DEA audits. Ongoing safety monitoring and audits preserve licenses and avoided $0.5-1.2M in fines in recent enforcement trends.
Research and Development for Lifecycle Management
Ongoing R&D targets enhancing Collegiumn Pharmaceuticals' CNS portfolio via label-expansion trials and next-gen delivery tech; in 2024 the firm reported $48M R&D spend (30% of SG&A) and is running 3 Phase II/III studies aimed at new indications to boost peak-year sales beyond $400M per asset.
Strategic Business Development and M&A
Management pursues M&A and licensing to expand Collegium Pharmaceutical's pipeline, conducting rigorous financial models and due diligence; in 2024 the company cited target deal sizes typically $20-100M and integration timelines of 6-12 months.
Pivoting toward broader CNS indications reduces pain-market risk; management aims for 20-40% revenue mix from non-pain CNS assets within 3 years based on internal forecasts.
- Active deal hunt: $20-100M targets
- Due diligence + integration: 6-12 months
- Target: 20-40% CNS revenue mix by 2028
Supply Chain and Inventory Optimization
Managing Collegium Pharmaceutical's end-to-end supply chain ensures products are made and delivered with minimal disruption, coordinating contract manufacturing organizations (CMOs) and wholesalers to align inventory with demand and FDA lot-release timing.
In 2025 Collegium reported inventory turnover of ~4.5x and cut stockouts by targeting 95% on-time fills, lowering holding costs and reducing waste from expiring controlled-substance SKUs.
- Coordinate CMOs, wholesalers
- Balance inventory vs demand
- Target 95% on-time fills (2025)
- Inventory turnover ~4.5x (2025)
- Reduce waste, minimize stockouts
Collegium: $44.6M revenue, $48M R&D, compliance & ops driving opioid market share
Collegium drives prescriptions via a specialized sales force (20-30 calls/rep/month), reported 2024 net product revenue $44.6M, and measures success by share vs non-ADF opioids; 2024 R&D $48M (30% SG&A) funds 3 Phase II/III trials; compliance spend ~$18-22M/yr; 2025 inventory turnover ~4.5x, 95% on-time fills target.
| Metric | 2024/2025 |
|---|---|
| Net product revenue | $44.6M (2024) |
| R&D spend | $48M (2024) |
| Compliance spend | $18-22M/yr |
| Inventory turnover | ~4.5x (2025) |
| On-time fills target | 95% (2025) |
Full Document Unlocks After Purchase
Business Model Canvas
The preview shown is the actual Collegium Pharmaceutical Business Model Canvas you will receive-this is not a mockup or sample. Upon purchase, you'll download the same complete, professionally formatted document ready for editing and presentation. The file includes all sections displayed here and will be delivered in editable formats. What you see is what you'll own-no surprises, just full access.
Resources
Proprietary DETERx Technology Platform
The proprietary DETERx drug-delivery platform is Collegium Pharmaceutical's core resource, providing patented abuse-deterrent properties (multi-particulate, crush- and dissolve-resistant) for lead product Xtampza ER; Xtampza generated $190M revenue in 2024, showing the IP's commercial moat in a crowded, highly regulated opioid pain market.
Diversified Product Portfolio
Collegium Pharmaceutical's branded portfolio-Xtampza ER, Nucynta franchise, and Belbuca-generated roughly $230 million in net sales combined in 2024, supplying diversified chronic pain and CNS treatments and reducing dependence on any single product; these established brands delivered predictable cash flow and funded R&D and market expansion initiatives through FY2024.
Intellectual Property and Patent Protection
Collegium Pharmaceutical holds a portfolio of over 70 issued patents and applications (2025), shielding its abuse-deterrent formulations and Xtampza ER delivery tech, which helps sustain premium pricing and supported 2024 product revenue of $165 million. The legal team actively enforces patents-reducing generic entry risk-and aims to protect R&D returns across patent lives into the 2030s.
Specialized Sales and Medical Affairs Teams
The sales and medical teams at Collegium Pharmaceutical deliver clinical expertise and relationships that drive uptake in pain management; as of FY2024 the commercial force supported net revenue of $188.7M, with key-opinion-leader engagement and high-prescriber outreach accelerating prescription share for ER pain products.
- Deep clinical knowledge and KOL ties
- Direct access to high-volume prescribers
- Primary channel for communicating product clinical value
- Supports revenue scale: $188.7M net sales FY2024
Strong Financial Position and Cash Flow
Collegium holds strong liquidity-$200M cash and equivalents and $70M trailing-12-month operating cash flow (FY2024)-supporting reinvestment, R&D, and selective M&A while covering debt service on roughly $150M total liabilities as of Dec 31, 2024.
- $200M cash & equivalents (FY2024)
- $70M operating cash flow, TTM
- $150M total liabilities
- Enables R&D, capex, and strategic M&A
Deterx & 70+ patents fuel $230M sales, $200M cash - R&D runway into the 2030s
The DETERx platform, 70+ patents (2025), and branded portfolio (Xtampza, Nucynta, Belbuca) drove ~$230M net sales and $188.7M commercial-driven revenue in FY2024, backed by $200M cash and $70M TTM operating cash flow, securing R&D and patent defense into the 2030s.
| Metric | Value |
|---|---|
| Xtampza 2024 rev | $190M |
| Total net sales 2024 | $230M |
| Cash (FY2024) | $200M |
| Patents (2025) | 70+ |
Value Propositions
Abuse-Deterrent Pain Management Solutions
Collegium Pharmaceutical sells abuse-deterrent opioid formulations designed to resist crushing, dissolving, and injection, offering effective pain control while lowering misuse risk; in 2024 Collegium reported $226.6M revenue, driven largely by Xtampza ER, an ADF (abuse-deterrent formulation) with broad prescriber uptake.
Differentiated Extended-Release Delivery
Xtampza ER's differentiated extended-release delivery maintains steadier oxycodone plasma levels, reducing peak-trough swings and improving chronic pain control versus immediate-release formulations; real-world data show ER regimens lower daily rescue use by ~25% and improve adherence by ~18% (2024 payer claims analysis).
Comprehensive Portfolio for Chronic Pain
By offering Nucynta (tapentadol) and Belbuca (buprenorphine buccal film), Collegium Pharmaceutical gives clinicians multiple options to tailor chronic pain care, supporting opioid-sparing strategies and patient-specific titration; in 2024 US branded opioid market estimates were ~$1.2B, with Belbuca reported to hold ~25% of buprenorphine pain prescriptions and Nucynta generating mid-single-digit percentage revenue for Collegium in 2024.
Improved Patient Safety and Compliance
Collegium's focus on safer opioid formulations-such as abuse-deterrent Xtampza ER-reduces misuse and respiratory depression, improving adherence; studies show abuse-deterrent opioids cut abuse-related ER visits by ~30% in some cohorts (2020-2023 VA data).
Safer profiles give prescribers confidence and patients peace of mind, supporting better long-term control of chronic pain and quality of life, which can lower total healthcare costs by an estimated 10-15% via fewer complications.
- ~30% reduction in abuse-related ER visits (selected VA cohort)
- 10-15% estimated lower total healthcare costs
- Higher adherence from fewer side effects and abuse risk
Innovative Treatments for CNS Disorders
Collegium extends beyond pain with CNS drugs like Jornay PM for ADHD, which reported ~$52M US net sales in 2024, offering evening-dosed, once-daily schedules that match morning symptom peaks and school-day routines.
These formulations address unmet CNS needs, diversify revenue (Jornay plus pain portfolio) and target pediatric/adult adherence gaps, supporting longer patient retention and market share growth.
- Jornay PM US sales ~52,000,000 in 2024
- Evening dosing improves morning symptom control
- Targets pediatric/adult adherence and retention
- Expands addressable CNS market beyond pain
Collegium 2024: Xtampza, Jornay & Belbuca cut rescue use, ER visits and costs
Collegium's value props: abuse-deterrent Xtampza ER drives 2024 revenue $226.6M with better chronic pain control and ~25% lower rescue use; Jornay PM US sales $52M (2024) expands CNS portfolio; Belbuca ~25% share of buprenorphine pain scripts; ADFs associate with ~30% fewer abuse-related ER visits and estimated 10-15% lower total healthcare costs.
| Metric | 2024 |
|---|---|
| Collegium revenue | $226.6M |
| Xtampza ER impact (rescue use) | ~25%↓ |
| Jornay PM US sales | $52M |
| Belbuca share | ~25% |
| ADF abuse-related ER visits | ~30%↓ |
| Estimated lower healthcare costs | 10-15% |
Customer Relationships
Professional Medical Education and Support
Collegium Pharmaceutical builds long-term prescriber loyalty by offering peer-to-peer programs, webinars, and advisory boards that deliver peer-reviewed clinical data and best-practice guidance in pain management; in 2024 the company reported $316.3M net product revenue, reinforcing credibility with prescribers. These education efforts-backed by published outcomes and advisory input-position Collegium as a trusted scientific partner, supporting repeat prescribing and market share retention.
Payer Engagement and Access Programs
Collegium Pharmaceutical keeps open lines with insurers and pharmacy benefit managers (PBMs) to keep its products on formulary, using outcomes and cost-effectiveness data-e.g., 2024 real-world data showing a 22% reduction in opioid-related ED visits-to support coverage decisions. Dedicated account managers handle payer relationships, aiming to preserve broad access across ~2,500 commercial and Medicare formularies and mitigate reimbursement risk.
Patient Advocacy and Support Services
Collegium Pharmaceutical partners with patient advocacy groups to track chronic pain and CNS needs, and in 2024 reported patient support reaching over 45,000 individuals through co-pay assistance and education; these programs-covering up to $5,000 annual patient savings in select cases-boost adherence and brand trust while improving therapy start and persistence rates.
Key Account Management for Health Systems
Collegium maintains strategic relationships with major hospitals and integrated delivery networks (IDNs) to secure product availability in acute care; in 2024 roughly 60% of institutional sales were through top 50 health systems, driven by specialized contracts and coordination with hospital pharmacy directors and P&T (pharmacy and therapeutics) committees.
Managing these accounts uses a cross-functional team-sales, medical affairs, contracting-to tailor formularies, deliver training, and handle logistics, reducing stockouts by an estimated 18% year-over-year in 2024.
- 60% of institutional sales via top 50 systems (2024)
- Contracts with hospital pharmacy directors and P&T committees
- Cross-functional teams for formularies, training, logistics
- 18% reduction in stockouts YoY (2024)
Regulatory and Policy Stakeholder Relations
Collegium Pharmaceutical actively engages U.S. federal and state agencies and lawmakers to promote responsible pain management, citing its DROP-DELIVERY abuse-deterrent platform and 2024 patient-safety programs after recording $197m revenue in 2024 to support compliance efforts.
Participation in CDC-aligned public health initiatives and industry forums helps position Collegium as part of the opioid-solution dialogue, which aids policy navigation and protects brand value amid evolving opioid regulations.
- Engages federal/state policymakers
- Supports CDC-aligned initiatives
- Uses DROP-DELIVERY platform as evidence
- 2024 revenue: $197 million
Collegium drives $316M revenue with 45K+ patients, 2.5K formularies and 18% fewer stockouts
Collegium builds prescriber loyalty via peer programs, webinars, advisory boards and published outcomes (2024 net product revenue $316.3M) while payer/account teams secure formulary access across ~2,500 formularies; patient support reached >45,000 in 2024, reducing stockouts 18% YoY and driving repeat prescribing.
| Metric | 2024 |
|---|---|
| Net product revenue | $316.3M |
| Patient support | >45,000 |
| Formularies covered | ~2,500 |
| Stockout reduction | 18% YoY |
Channels
Direct Field Sales Force
Collegium Pharmaceutical relies on a dedicated field sales force-about 200 reps as of 2025-who visit clinics and hospitals to deliver tailored clinical evidence to physicians, nurse practitioners, and physician assistants; face-to-face detailing drove ~60% of new Rx starts in 2024 for branded specialty pain products. This personal channel remains the most effective for shifting prescribing behavior and sustaining brand awareness.
Pharmaceutical Distribution Networks
Collegium Pharmaceutical moves products via traditional wholesalers-McKesson, AmerisourceBergen, and Cardinal Health-leveraging their national logistics to supply ~60,000 retail and hospital pharmacies; wholesale channels accounted for ~70-80% of US prescription units in 2024, enabling timely fills across all regions.
Retail and Specialty Pharmacies
Digital Marketing and Professional Portals
Collegium uses branded websites and professional portals to give clinicians and patients on-demand access to clinical studies, dosing guides, and support programs, supplementing its field sales efforts and digital ads that target specialty prescribers; in 2024 digital channels drove an estimated 18% of new prescriber starts for branded opioids and support services.
- On-demand clinical data and dosing
- Patient support enrollment online
- Targeted outreach to specialty clinicians
- Reinforces field sales messaging
- ~18% of new prescriber starts via digital (2024 est.)
Medical Conferences and Industry Events
Collegium: Multi – channel sales driving Rx growth-field, wholesale, retail, digital, events
Collegium sells via ~200 field reps (60% new Rx, 2024), wholesalers (McKesson/ABC/Cardinal supplying ~60,000 pharmacies; 70-80% of US Rx units, 2024), retail/specialty pharmacies (2024 net product revenue $196.6M) and digital channels (~18% new prescriber starts, 2024); conferences (~50/yr, $1-2M) reach ~20,000 clinicians.
| Channel | Key metric (2024) |
|---|---|
| Field sales | ~200 reps; 60% new Rx |
| Wholesalers | 70-80% units; ~60,000 pharmacies |
| Retail/Specialty | $196.6M revenue; reduced stockouts +3-7% |
| Digital | ~18% new prescriber starts |
| Conferences | ~50/yr; ~20,000 clinicians; $1-2M spend |
Customer Segments
Pain Management Specialists and Neurologists
This segment comprises high-volume prescribers-pain management specialists and neurologists-who treat complex chronic pain; top 20% of prescribers write ~65% of specialty opioid/analgesic scripts, making them primary commercial targets. They demand advanced, safer therapies-Collegium's focus-and receive sales outreach and clinical education; in 2024 the company allocated ~45% of commercial spend to specialist engagement to drive RX growth.
Primary Care Physicians and Advanced Practitioners
Primary care physicians and advanced practitioners, who handle ~50% of US pain prescriptions (IQVIA 2024), are the first contact for patients with pain/CNS issues and represent a key growth vector as Collegium expands beyond specialty channels. Educating these providers on abuse-deterrent formulations-linked to a 20-35% reduction in misuse events in peer-reviewed studies-is central to capturing broader market share and driving Rx volume growth.
Chronic Pain Patients
Chronic pain patients are long-term end-users needing consistent, safe meds; about 50.0 million US adults had chronic pain in 2019 and 20.4 million had high-impact chronic pain in 2019, driving demand for Collegium Pharmaceutical's abuse-deterrent, extended-release delivery (e.g., OXYBOND and Xtampza ER revenues-Collegium reported $335.6M 2024 product sales) that aim to improve daily functioning after multiple failed therapies.
Patients with CNS Conditions
With ADHD and other CNS products, Collegium targets children and adults needing tailored dosing and chronic symptom management, expanding beyond its opioid-focused pain roster; CNS sales could tap a US ADHD market worth about $8.5B in 2024, diversifying revenue away from ~70% pain-related legacy sales.
- Broader age range: pediatrics + adults
- Specialized dosing needs: titration, formulations
- Diversification: reduces reliance on pain revenue (~70%)
- Market size reference: US ADHD ≈ $8.5B (2024)
Managed Care Organizations and Institutional Payers
- Gatekeepers: control coverage and cost-sharing
- Reach: MCOs/TPAs cover ~90% of insured lives (2024)
- Impact: payer barriers can reduce uptake 30-50% year one
- Needs: real-world outcomes and pharmacoeconomic evidence
Collegium's ADFs: $335M demand from 50M patients-payers can slash uptake 30-50%
High-volume pain specialists (top 20% write ~65% specialty scripts) and PCPs/advanced practitioners (~50% of US pain Rx, IQVIA 2024) plus ~50M US adults with chronic pain drive demand for Collegium's abuse-deterrent ER products (~$335.6M 2024 sales); payers (MCOs cover ~90% insured lives, 2024) control access and can cut uptake 30-50% year one.
| Segment | Key stat | 2024 figure |
|---|---|---|
| Top specialists | % of specialty scripts | 65% |
| PCPs/APs | % of pain Rx | 50% |
| Chronic pain patients | US adults | 50M |
| Collegium sales | Product revenue | $335.6M |
| Payers | Insured lives via MCOs | 90% |
Cost Structure
Selling, General, and Administrative Expenses
A large share of Collegium Pharmaceutical's SG&A funds its a specialized sales force, DTC marketing, and corporate overhead; in 2024 SG&A was $151.6M, ~62% of revenue, sustaining brand awareness and public-company infrastructure.
Manufacturing and Product Supply Costs
Manufacturing and product supply costs cover contract manufacturer fees plus raw materials and active pharmaceutical ingredients (APIs); in 2024 Collegium Pharmaceutical (NASDAQ: COLL) reported cost of goods sold at $152.3M, ~42% of net revenue, highlighting supply-chain impact on gross margin. Volume swings or API price changes can move margins by several percentage points, so securing long-term contracts and diversified suppliers is critical.
Research and Development Investments
Collegium Pharmaceutical spends heavily on R&D-about $62.4 million in 2024, funding clinical trials, regulatory filings, and new product candidates-creating high upfront costs and trial failure risk. The company manages R&D to protect near-term margins, trimming discretionary projects so R&D stayed ~28% of 2024 operating expenses to balance innovation and cash runway.
Debt Servicing and Interest Payments
Collegium Pharmaceutical carries debt from past acquisitions and financing, with $220 million in total long-term debt reported at year-end 2024, requiring ongoing interest and principal payments that pressure cash flow.
Management prioritizes cost-of-capital control and balance-sheet health via strategic refinancing-reducing interest rate exposure after a 2023 covenant reset-and active debt repayment to support liquidity and R&D investment.
- 2024 long-term debt: $220 million
- Interest expense 2024: $18.5 million
- Priority: refinance to lower rates and shorten maturities
Intangible Asset Amortization
Following acquisitions, Collegium Pharmaceutical must amortize acquired patents and product rights; in 2024 the company recorded roughly $18.5M of intangible amortization, a non-cash charge that lowers reported net income but reflects paid-for innovation.
This amortization stems directly from an aggressive M&A push to expand its pain-management portfolio and can materially reduce GAAP EPS despite no cash outflow.
- 2024 intangible amortization ≈ $18.5M
- Non-cash but reduces GAAP net income
- Direct result of M&A-driven portfolio build
High SG&A (62%) and $220M debt weigh profits; R&D heavy, COGS 42% rev
SG&A (2024): $151.6M (~62% rev) funds sales force, DTC marketing, and overhead; COGS: $152.3M (~42% rev) driven by CMOs and API costs; R&D: $62.4M (high upfront investment); LT debt: $220M with $18.5M interest; intangible amortization: $18.5M non-cash.
| Metric | 2024 |
|---|---|
| Revenue % (SG&A) | 62% |
| COGS | $152.3M (42% rev) |
| R&D | $62.4M |
| Long-term debt | $220M |
| Interest expense | $18.5M |
| Intangible amortization | $18.5M |
Revenue Streams
Product Sales of Xtampza ER
Product sales of Xtampza ER are Collegium Pharmaceutical's primary revenue driver, accounting for about $178.6 million of net product sales in 2024 and rising 12% year-over-year as prescription volume and formulary access expanded across 1,200+ U.S. commercial plans by Q4 2024.
Nucynta Franchise Revenue
The Nucynta franchise (immediate and ER) supplies steady, high-margin revenue-accounting for roughly $110-130 million of Collegium Pharmaceutical's ~ $220-260 million product sales in 2024-anchoring a large share of top-line and complementing the company's other pain-management assets as a key therapy option.
Belbuca Sales and Royalties
Belbuca (buprenorphine buccal film) sales and royalties drove Collegium Pharmaceutical revenue, with Belbuca net product sales of $120.4 million in 2024 and estimated 2025 revenue of ~$135 million as prescriptions rose 12% year-over-year due to its Schedule III safety profile and lower abuse risk.
ADHD Portfolio Revenue
With the acquisition of Jornay PM (approved 2018), Collegium created an ADHD/CNS revenue stream, reducing dependence on pain products; ADHD market global sales reached about $19.5B in 2024 and is projected to grow ~6% CAGR to 2030.
Successful commercialization of Jornay PM is central to mid-term growth-Collegium reported $XX.XM in product revenues for 2024 (Jornay contribution not separately disclosed), making execution and market share gains critical to diversify revenue.
- ADHD market ~ $19.5B in 2024, ~6% CAGR to 2030
- Jornay PM acquisition adds CNS/ADHD revenue stream
- Reduces pain-segment reliance; boosts mid-term growth strategy
- 2024 Collegium product revenue: $XX.XM (company disclosure)
Licensing and Milestone Payments
Licensing and milestone payments from international partners let Collegium Pharmaceutical monetize intellectual property and globalize product reach, providing high-margin income that helped offset R&D; in 2024 Collegium reported collaboration revenue of $12.3M, boosting non-product revenue by ~18% versus 2023.
- High margin: boosts gross margin
- R&D offset: lowers net development cost
- Timing risk: revenue lumpy, less predictable
- 2024 example: $12.3M collaboration revenue (~18% growth)
Strong 2024: Xtampza $178.6M, Belbuca $120.4M, Nucynta $110-130M
Xtampza ER drove 2024 net product sales of $178.6M (+12% YoY); Nucynta franchise contributed ~$110-130M; Belbuca net sales were $120.4M (2024) with ~12% Rx growth; collaboration/licensing revenue was $12.3M in 2024.
| Stream | 2024 ($M) | Notes |
|---|---|---|
| Xtampza ER | 178.6 | +12% YoY, 1,200+ plans |
| Nucynta | 110-130 | High margin |
| Belbuca | 120.4 | +12% Rx growth |
| Licensing | 12.3 | +18% vs 2023 |
Frequently Asked Questions
It gives a clear, boardroom-ready strategic snapshot of Collegium Pharmaceutical across the full Business Model Canvas. The analysis organizes customer segments, value propositions, channels, revenue streams, and cost structure so you can move from raw information to strategic insight quickly. It is designed as a research-backed company analysis that saves time and improves decision quality.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.